Charleston News Online

Chronic Kidney Disease Pipeline Assessment, Key Companies, And Emerging Drugs

Chronic Kidney Disease Pipeline Assessment, Key Companies, And Emerging Drugs

April 23
16:44 2021
Chronic Kidney Disease Pipeline Assessment, Key Companies, And Emerging Drugs

Delveinsight Business Research LLP

“Chronic Kidney Disease Pipeline Insight, 2021” report by DelveInsight outlines comprehensive insights of present clinical development scenario and growth prospects across the Chronic Kidney Disease Market.

The Chronic Kidney Disease Pipeline report embraces in-depth commercial and clinical assessment of the Chronic Kidney Disease pipeline products from the pre-clinical developmental phase to the marketed phase. 

The report covers a detailed description of the drug including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Chronic Kidney Disease collaborations, mergers, acquisition, funding, designations, and other product-related details.

Get FREE sample copy at

The market size of Chronic Kidney Disease (CKD) is anticipated to increase during the study period, owing to the increasing prevalent population of Chronic Kidney Disease (CKD) patients in the 7MM, along with the expected entry of premium price asset such Anti-inflammatories, Prolyl hydroxylase and IL-6 inhibitors.

Chronic Kidney Disease Companies:
Akebia Therapeutics
Astellas Pharma
Boehringer Ingelheim
Astra Zeneca
Reata Pharmaceuticals
Corvidia Therapeutics
And many others.

Chronic Kidney Disease Therapies covered in the report include:
Bardoxolone Methyl
And many others.

Chronic Kidney Disease Pipeline Analysis

Chronic Kidney Disease Pipeline Analysis

The report provides insights into: 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Chronic Kidney Disease with aggregate therapies developed by each company for the same.

  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late stage of development for the Chronic Kidney Disease Treatment.

  • Chronic Kidney Disease key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • Chronic Kidney Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Chronic Kidney Disease market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.  

Scope of the report

  • The Chronic Kidney Disease Pipeline Report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Chronic Kidney Disease across the complete product development cycle, including all clinical and non-clinical stages.

  • It comprises detailed profiles of Chronic Kidney Disease therapeutic products with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

  • Detailed research and development progress and clinical trial of Chronic Kidney Disease, results wherever available, are also included in the pipeline study.

  • Coverage of dormant and discontinued pipeline projects along with the reasons if available across Chronic Kidney Disease.

Report Highlights

  • A better understanding of disease pathogenesis contributing to the development of novel therapeutics for Chronic Kidney Disease.    

  • In the coming years, the Chronic Kidney Disease market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market. 

  • The companies and academics are working to assess challenges and seek opportunities that could influence Chronic Kidney Disease Research & Development. The therapies under development are focused on novel approaches to treat/improve the disease condition.

  • A detailed portfolio of major pharma players who are involved in fueling the Chronic Kidney Disease treatment market. Several potential therapies for Chronic Kidney Disease are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Chronic Kidney Disease market size in the coming years.  

  • Our in-depth analysis of the Chronic Kidney Disease pipeline assets (in early-stage, mid-stage, and late stage of development) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities. 

Table of Content

1. Report Introduction

2. Chronic Kidney Disease 

3. Chronic Kidney Disease Current Treatment Patterns

4. Chronic Kidney Disease – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Chronic Kidney Disease Late Stage Products (Phase-III)

7. Chronic Kidney Disease Mid Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Chronic Kidney Disease Discontinued Products

13. Chronic Kidney Disease Product Profiles

14. Chronic Kidney Disease Key Companies

15. Chronic Kidney Disease Key Products

16. Dormant and Discontinued Products

17. Chronic Kidney Disease Unmet Needs

18. Chronic Kidney Disease Future Perspectives

19. Chronic Kidney Disease Analyst Review  

20. Appendix

21. Report Methodology
*The table of contents is not exhaustive; the final content may vary. 

Latest Healthcare Reports By DelveInsight – 
Chronic Kidney Disease Market
DelveInsight’ s “Chronic Kidney Disease (Chronic Renal Failure) Market Insights, Epidemiology and Market Forecast – 2030” report provides a detailed overview of the disease and an in-depth analysis of the Chronic Kidney Disease market trends in the 7MM.

Interspinous Spacers Market Insights and Competitive Landscape
DelveInsight’s “Interspinous Spacers Market Insights, Competitive Landscape and Market Forecast – 2025” report delivers an in-depth understanding of the historical and forecasted Interspinous Spacers market size, share, trends, forecast and market growth prospects in the US, EU5 (Germany, Spain, Italy, France and the United Kingdom) and Japan.

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States

About Author



Related Articles